MedPath

Aerobic Training in Metastatic Breast Cancer

Not Applicable
Completed
Conditions
Metastatic Breast Cancer
Interventions
Behavioral: Nonlinear Aerobic Training
Behavioral: Progressive Stretching Group
Other: Blood draw
Other: Cardiopulmonary Exercise Testing (CPET)
Registration Number
NCT01725633
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Brief Summary

This study is being done to examine the safety and feasibility of a supervised progressive exercise program in women diagnosed with metastatic breast cancer. Previous research among women with metastatic breast cancer has shown that some of the treatments commonly used in this population may have an adverse impact on physical fitness levels leading to feelings of fatigue and poor quality of life. Supervised exercise training has been shown to reduce some of these side-effects in women with early-stage breast cancer receiving common cancer treatments. However, it is not known if supervised exercise training is a safe and feasible intervention in women with metastatic breast cancer. This study is designed to find out if supervised exercise training is safe as the patients undergo treatments for metastatic breast cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
27
Inclusion Criteria
  • MSK histologically confirmed metastatic breast cancer

  • Measurable disease (or nonmeasurable bone-only disease) assessed by CT or PET/CT performed as part of standard of care, at the discretion of the attending oncologist in the Breast Medicine Service

  • ≥18 years of age;

  • Life expectancy >3 months;

  • ECOG ≤ 1

  • Sedentary, as per the leisure score index (LSI) of the Godin Leisure-Time Exercise Questionnaire (GLTEQ) . Participants who perform regular moderate or vigorous intensity exercise at least 5 days/week, for at least 30 minutes/session, are not eligible

  • Able to achieve an acceptable peak baseline CPET, as defined by any of the following criteria:

    1. Achieving a plateau in oxygen consumption, concurrent with an increase in power output;
    2. A respiratory exchange ratio ≥ 1.10;
    3. Attainment of maximal predicted heart rate (HRmax) (i.e., within 10 bpm of age-predicted HRmax [HRmax = 220-Age[years]);
    4. Volitional exhaustion, as measured by a rating of perceived exertion (RPE) ≥ 18 on the BORG scale
  • Normal cardiac function (left ventricular ejection fraction ≥50%);

  • Medical clearance from attending oncologist indicating no relative contraindications to undergo a symptom-limited cardiopulmonary exercise test and aerobic training intervention;

  • Patients with "treated and stable" brain lesions of a duration of ≥ 2 months may be enrolled

  • Willing to be randomized to one of the study arms

  • Female

Read More
Exclusion Criteria
  • Any of the following absolute contraindications to cardiopulmonary exercise testing:

    1. Acute myocardial infarction within 3-5 days of any planned study procedures
    2. Unstable angina
    3. Uncontrolled arrhythmia causing symptoms or hemodynamic compromise;
    4. Recurrent syncope
    5. Active endocarditis;
    6. Acute myocarditis or pericarditis
    7. Symptomatic severe aortic stenosis
    8. Uncontrolled heart failure
    9. Acute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures
    10. Thrombosis of lower extremities
    11. Suspected dissecting aneurysm
    12. Uncontrolled asthma
    13. Pulmonary edema
    14. Room air desaturation at rest ≤ 85%
    15. Respiratory failure
    16. Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis)
    17. Mental impairment leading to inability to cooperate.
  • Any other condition or intercurrent illness that, in the opinion of the investigator, makes the participant a poor candidate for the trial

  • Presence of extensive skeletal metastases, defined as more than five (5) sites of bony disease, or any symptomatic site of disease in the spine, hip, or femur. Note that, patients with more than five bony sites may be deemed eligible at the discretion of the attending oncologist.

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Progressive Stretching GroupBlood draw-
Nonlinear Aerobic TrainingNonlinear Aerobic Training-
Progressive Stretching GroupProgressive Stretching Group-
Nonlinear Aerobic TrainingBlood draw-
Nonlinear Aerobic TrainingCardiopulmonary Exercise Testing (CPET)-
Primary Outcome Measures
NameTimeMethod
safety of aerobic training2 years

Safety will be evaluated by the type and prevalence of adverse events during study-related assessments as well as aerobic training and progressive stretching sessions. The NCI Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE) will be used to grade toxicities during the trial.

Secondary Outcome Measures
NameTimeMethod
feasibility of aerobic training2 years

feasibility will be evaluated by examining several different end points including rates of study eligibility and accrual, etc; however, sample size calculations are based on an integration of aerobic training attendance rate (in the aerobic training group) as well as global trial attrition rates. Together, these end points will be used to determine overall study feasibility.

Trial Locations

Locations (2)

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

Memorial Sloan Kettering Cancer Center

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath